-
1
-
-
0035902108
-
Genome maintenance mechanisms for preventing cancer
-
Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001; 411: 366-374.
-
(2001)
Nature
, vol.411
, pp. 366-374
-
-
Hoeijmakers, J.H.1
-
4
-
-
33646582299
-
Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway
-
Chirnomas D, Taniguchi T, de la Vega M et al. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther 2006; 5: 952-961.
-
(2006)
Mol Cancer Ther
, vol.5
, pp. 952-961
-
-
Chirnomas, D.1
Taniguchi, T.2
de la Vega, M.3
-
5
-
-
52949096470
-
Genetic predisposition to breast cancer: past, present, and future
-
Turnbull C, Rahman N. Genetic predisposition to breast cancer: past, present, and future. Annu Rev Genomics Hum Genet 2008; 9: 321-345.
-
(2008)
Annu Rev Genomics Hum Genet
, vol.9
, pp. 321-345
-
-
Turnbull, C.1
Rahman, N.2
-
6
-
-
40349108598
-
On the dynamics of breast tumor development in women carrying germline BRCA1 and BRCA2 mutations
-
Simon R, Zhang X. On the dynamics of breast tumor development in women carrying germline BRCA1 and BRCA2 mutations. Int J Cancer 2008; 122: 1916-1917.
-
(2008)
Int J Cancer
, vol.122
, pp. 1916-1917
-
-
Simon, R.1
Zhang, X.2
-
7
-
-
77950650763
-
Germline BRCA mutations denote a clinicopathologic subset of prostate cancer
-
Gallagher DJ, Gaudet MM, Pal P et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res 2010; 16: 2115-2121.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 2115-2121
-
-
Gallagher, D.J.1
Gaudet, M.M.2
Pal, P.3
-
8
-
-
62849118739
-
Potential excess mortality in BRCA1/2 mutation carriers beyond breast, ovarian, prostate, and pancreatic cancers. melanoma
-
Mai PL, Chatterjee N, Hartge P et al. Potential excess mortality in BRCA1/2 mutation carriers beyond breast, ovarian, prostate, and pancreatic cancers. melanoma. PloS one 2009; 4: e4812.
-
(2009)
PloS one
, vol.4
-
-
Mai, P.L.1
Chatterjee, N.2
Hartge, P.3
-
9
-
-
64949184079
-
A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma
-
Kefford RF, Thomas NP, Corrie PG et al. A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma. Br J Cancer 2009; 100: 1245-1249.
-
(2009)
Br J Cancer
, vol.100
, pp. 1245-1249
-
-
Kefford, R.F.1
Thomas, N.P.2
Corrie, P.G.3
-
11
-
-
0018906390
-
(ADP-ribose)n participates in DNA excision repair
-
Durkacz BW, Omidiji O, Gray DA et al. (ADP-ribose)n participates in DNA excision repair. Nature 1980; 283: 593-596.
-
(1980)
Nature
, vol.283
, pp. 593-596
-
-
Durkacz, B.W.1
Omidiji, O.2
Gray, D.A.3
-
12
-
-
0019844233
-
Inhibitors of nuclear ADP-ribosyl transferase retard DNA-repair after N-methyl-N-nitroso-urea - further evidence for the involvement of (ADP-ribose)n in DNA-repair
-
Gray DA, Durkacz BW, Shall S. Inhibitors of nuclear ADP-ribosyl transferase retard DNA-repair after N-methyl-N-nitroso-urea - further evidence for the involvement of (ADP-ribose)n in DNA-repair. FEBS Lett 1981; 131: 173-177.
-
(1981)
FEBS Lett
, vol.131
, pp. 173-177
-
-
Gray, D.A.1
Durkacz, B.W.2
Shall, S.3
-
13
-
-
0033941729
-
Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines
-
Delaney CA, Wang LZ, Kyle S et al. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res 2000; 6: 2860-2867.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 2860-2867
-
-
Delaney, C.A.1
Wang, L.Z.2
Kyle, S.3
-
14
-
-
12444276597
-
Identification of potent non-toxic novel poly(ADP-ribose)polymerase-1 inhibitors. Chemopotentiation and pharmacological studies
-
Calabrese CR, Batey MA, Thomas HD et al. Identification of potent non-toxic novel poly(ADP-ribose)polymerase-1 inhibitors. Chemopotentiation and pharmacological studies. Clini Cancer Res 2003; 9: 2711-2718.
-
(2003)
Clini Cancer Res
, vol.9
, pp. 2711-2718
-
-
Calabrese, C.R.1
Batey, M.A.2
Thomas, H.D.3
-
15
-
-
59449085305
-
Phase I study of the poly (ADPribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors
-
Plummer R, Jones C, Middleton M et al. Phase I study of the poly (ADPribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2008; 14: 7917-7923.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 7917-7923
-
-
Plummer, R.1
Jones, C.2
Middleton, M.3
-
16
-
-
17244375049
-
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
-
Bryant HE, Schultz N, Thomas HD et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 913-917.
-
(2005)
Nature
, vol.434
, pp. 913-917
-
-
Bryant, H.E.1
Schultz, N.2
Thomas, H.D.3
-
17
-
-
17244373777
-
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
-
Farmer H, McCabe1 N, Lord C et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-921.
-
(2005)
Nature
, vol.434
, pp. 917-921
-
-
Farmer, H.1
McCabe1, N.2
Lord, C.3
-
18
-
-
67650476607
-
Synthetic lethality-a new direction in cancer-drug development
-
Iglehart JD, Silver DP. Synthetic lethality-a new direction in cancer-drug development. N Engl J Med 2009; 361: 189-191.
-
(2009)
N Engl J Med
, vol.361
, pp. 189-191
-
-
Iglehart, J.D.1
Silver, D.P.2
-
19
-
-
33947380240
-
Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology
-
Ratnam K, Low JA. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res 2007; 13: 1383-1388.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 1383-1388
-
-
Ratnam, K.1
Low, J.A.2
-
20
-
-
0037151051
-
Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1
-
Schreiber V, AmeJC Dolle P et al. Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J Biol Chem 2002; 277: 23028-23036.
-
(2002)
J Biol Chem
, vol.277
, pp. 23028-23036
-
-
Schreiber, V.1
Ame, J.C.2
Dolle, P.3
-
21
-
-
0034733694
-
Base excision repair in yeast and mammals
-
Memisoglu A, Samson L. Base excision repair in yeast and mammals. Mutat Res 2000; 451: 39-51.
-
(2000)
Mutat Res
, vol.451
, pp. 39-51
-
-
Memisoglu, A.1
Samson, L.2
-
22
-
-
34147182310
-
Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial
-
Thomas HD, Calabrese CR, Batey MA et al. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther 2007; 6: 945-956.
-
(2007)
Mol Cancer Ther
, vol.6
, pp. 945-956
-
-
Thomas, H.D.1
Calabrese, C.R.2
Batey, M.A.3
-
23
-
-
70349659952
-
Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo?
-
Ali M, Telfer BA, McCrudden C et al. Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo? Clin Cancer Res 2009; 15: 6106-6112.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 6106-6112
-
-
Ali, M.1
Telfer, B.A.2
McCrudden, C.3
-
24
-
-
79551616892
-
-
Abstract #36. The Hereditary Breast and Ovarian Cancers (HBOC) Meeting, 10/12 September, Bari, Italy
-
Azzariti A, Porcelli L, Simone GM et al. In vitro charactherization of AG16499, a PARP inhibitor, in breast and pancreas cancer models. Abstract #36. The Hereditary Breast and Ovarian Cancers (HBOC) Meeting, 10/12 September 2009, Bari, Italy.
-
(2009)
In vitro charactherization of AG16499, a PARP inhibitor. in breast and pancreas cancer models
-
-
Azzariti, A.1
Porcelli, L.2
Simone, G.M.3
-
25
-
-
38949141134
-
Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells
-
Azzariti A, Porcelli L, Gatti G et al. Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells. Biochem Pharmacol 2008; 75: 1035-1044.
-
(2008)
Biochem Pharmacol
, vol.75
, pp. 1035-1044
-
-
Azzariti, A.1
Porcelli, L.2
Gatti, G.3
-
26
-
-
10744233628
-
Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repairdeficient cells
-
Curtin NJ, Wang LZ, Yiakouvaki A et al. Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repairdeficient cells. Clin Cancer Res 2004; 10: 881-889.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 881-889
-
-
Curtin, N.J.1
Wang, L.Z.2
Yiakouvaki, A.3
-
27
-
-
63149128657
-
Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma
-
Daniel RA, Rozanska AL, Thomas HD et al. Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. Clin Cancer Res 2009; 15: 1241-1249.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 1241-1249
-
-
Daniel, R.A.1
Rozanska, A.L.2
Thomas, H.D.3
-
28
-
-
54549103449
-
4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phth alazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1
-
Menear KA, Adcock C, Boulter R et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phth alazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem 2008; 51: 6581-6591.
-
(2008)
J Med Chem
, vol.51
, pp. 6581-6591
-
-
Menear, K.A.1
Adcock, C.2
Boulter, R.3
-
29
-
-
55949092708
-
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
-
Rottenberg S, Jaspers JE, Kersbergen A et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 2008; 105: 17079-17084.
-
(2008)
Proc Natl Acad Sci USA
, vol.105
, pp. 17079-17084
-
-
Rottenberg, S.1
Jaspers, J.E.2
Kersbergen, A.3
-
30
-
-
33751278712
-
Cellular functions of the BRCA tumoursuppressor proteins
-
Boulton SJ. Cellular functions of the BRCA tumoursuppressor proteins. Biochem Soc Trans 2006; 34: 633-645.
-
(2006)
Biochem Soc Trans
, vol.34
, pp. 633-645
-
-
Boulton, S.J.1
-
31
-
-
52449111109
-
Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin
-
Evers B, Drost R, Schut E et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res 2008; 14: 3916-3925.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 3916-3925
-
-
Evers, B.1
Drost, R.2
Schut, E.3
-
32
-
-
65949095892
-
Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin
-
Hay T, Matthews JR, Pietzka L et al. Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin. Cancer Res 2009; 69: 3850-3855.
-
(2009)
Cancer Res
, vol.69
, pp. 3850-3855
-
-
Hay, T.1
Matthews, J.R.2
Pietzka, L.3
-
33
-
-
74949093142
-
A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors
-
Evers B, Schut E, van der Burg E et al. A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors. Clin Cancer Res 2010; 16: 99-108.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 99-108
-
-
Evers, B.1
Schut, E.2
van der Burg, E.3
-
34
-
-
76749114340
-
Sensitivity and acquired resistance of BRCA1; p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan
-
Zander SA, Kersbergen A, van der Burg E et al. Sensitivity and acquired resistance of BRCA1; p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan. Cancer Res 2010; 70: 1700-1710.
-
(2010)
Cancer Res
, vol.70
, pp. 1700-1710
-
-
Zander, S.A.1
Kersbergen, A.2
van der Burg, E.3
-
35
-
-
34249006299
-
ABT-888, an orally active poly(ADPribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models
-
Donawho CK, Luo Y, Penning TD et al. ABT-888, an orally active poly(ADPribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007; 13: 2728-2737.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 2728-2737
-
-
Donawho, C.K.1
Luo, Y.2
Penning, T.D.3
-
36
-
-
54249167431
-
Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of singlestranded DNA damages to double-stranded DNA breaks
-
Liu X, Shi Y, Guan R et al. Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of singlestranded DNA damages to double-stranded DNA breaks. Mol Cancer Res 2008; 6: 1621-1629.
-
(2008)
Mol Cancer Res
, vol.6
, pp. 1621-1629
-
-
Liu, X.1
Shi, Y.2
Guan, R.3
-
37
-
-
68849128273
-
Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity
-
Horton TM, Jenkins G, Pati D et al. Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther 2009; 8: 2232-2242.
-
(2009)
Mol Cancer Ther
, vol.8
, pp. 2232-2242
-
-
Horton, T.M.1
Jenkins, G.2
Pati, D.3
-
38
-
-
73149110553
-
ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors
-
Palma JP, Wang YC, Rodriguez LE et al. ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin Cancer Res 2009; 15: 7277-7290.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 7277-7290
-
-
Palma, J.P.1
Wang, Y.C.2
Rodriguez, L.E.3
-
39
-
-
60849125726
-
Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines
-
Clarke MJ, Mulligan EA, Grogan PT et al. Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. Mol Cancer Ther 2009; 8: 407-414.
-
(2009)
Mol Cancer Ther
, vol.8
, pp. 407-414
-
-
Clarke, M.J.1
Mulligan, E.A.2
Grogan, P.T.3
-
40
-
-
72449148827
-
Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways
-
Liu X, Han EK, Anderson M et al. Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways. Mol Cancer Res 2009; 7: 1686-1692.
-
(2009)
Mol Cancer Res
, vol.7
, pp. 1686-1692
-
-
Liu, X.1
Han, E.K.2
Anderson, M.3
-
41
-
-
33644675410
-
Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft
-
Cheng CL, Johnson SP, Keir ST et al. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther 2005; 4: 1364-1368.
-
(2005)
Mol Cancer Ther
, vol.4
, pp. 1364-1368
-
-
Cheng, C.L.1
Johnson, S.P.2
Keir, S.T.3
-
42
-
-
77954951941
-
Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma
-
Toshimitsu H, Yoshimoto Y, Augustine CK et al. Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma. Ann Surg Oncol 2010; 17: 2247-2254.
-
(2010)
Ann Surg Oncol
, vol.17
, pp. 2247-2254
-
-
Toshimitsu, H.1
Yoshimoto, Y.2
Augustine, C.K.3
-
43
-
-
38149076469
-
INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin
-
Mason KA, Valdecanas D, Hunter NR, Milas L. INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin. Invest New Drugs 2008; 26: 1-5.
-
(2008)
Invest New Drugs
, vol.26
, pp. 1-5
-
-
Mason, K.A.1
Valdecanas, D.2
Hunter, N.R.3
Milas, L.4
-
44
-
-
79551577948
-
A review of PARP inhibitors: from bench to bedside
-
Jul 19 [Epub ahead of print]
-
Underhill C, Toulmonde M, Bonnefoi H. A review of PARP inhibitors: from bench to bedside. Ann Oncol 2010; Jul 19 [Epub ahead of print].
-
(2010)
Ann Oncol
-
-
Underhill, C.1
Toulmonde, M.2
Bonnefoi, H.3
-
45
-
-
68449096428
-
Efficacy of BSI-201, a poly(ADPribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial
-
(Abstr 3)
-
O'Shaughnessy J, Osborne C, Pippen J et al. Efficacy of BSI-201, a poly(ADPribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. J Clin Oncol 2009; 27: (Suppl 18): 793s (Abstr 3).
-
(2009)
J Clin Oncol
, vol.27
, Issue.SUPPL. 18
-
-
O'Shaughnessy, J.1
Osborne, C.2
Pippen, J.3
-
46
-
-
79551623114
-
-
Abstract #2311. 99th AACR Annual Meeting, 12-16 April; San Diego, CA, USA
-
Ossovskaya V, Li L, Bradley C et al. Activity of BSI-201, a potent poly(ADP-ribose) polymerase (PARP1) inhibitor, alone and in combination with topotecan in human ovarian xenografts. Abstract #2311. 99th AACR Annual Meeting, 12-16 April 2008; San Diego, CA, USA.
-
(2008)
Activity of BSI-201, a potent poly(ADP-ribose) polymerase (PARP1) inhibitor, alone and in combination with topotecan in human ovarian xenografts
-
-
Ossovskaya, V.1
Li, L.2
Bradley, C.3
-
47
-
-
33947379595
-
PARP inhibitors enhance the effect of cisplatin against tumors and ameliorate cisplatin-induced neuropathy
-
Lapidus RG, XuW Spicer E et al. PARP inhibitors enhance the effect of cisplatin against tumors and ameliorate cisplatin-induced neuropathy. Proc Am Assoc Cancer Res 2006; 47: A2141.
-
(2006)
Proc Am Assoc Cancer Res
, vol.47
-
-
Lapidus, R.G.1
Spicer, E.2
Xu, W.3
-
48
-
-
34548072788
-
The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity
-
Miknyoczki S, Chang H, Grobelny J et al. The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity. Mol Cancer Ther 2007; 6: 2290-2302.
-
(2007)
Mol Cancer Ther
, vol.6
, pp. 2290-2302
-
-
Miknyoczki, S.1
Chang, H.2
Grobelny, J.3
-
49
-
-
10744226451
-
Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361
-
Calabrese CR, Almassy R, Barton S et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 2004; 96: 56-67.
-
(2004)
J Natl Cancer Inst
, vol.96
, pp. 56-67
-
-
Calabrese, C.R.1
Almassy, R.2
Barton, S.3
-
50
-
-
35148894301
-
First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AGO14699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). Meeting Abstracts Part I
-
(Abstr 8013)
-
Plummer R, Lorigan P, Evans J et al. First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AGO14699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). Meeting Abstracts Part I. J Clin Oncol 2006; 24 (Suppl 18): 456S (Abstr 8013).
-
(2006)
J Clin Oncol
, vol.24
, Issue.SUPPL. 18
-
-
Plummer, R.1
Lorigan, P.2
Evans, J.3
-
51
-
-
67650471685
-
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers
-
Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-134.
-
(2009)
N Engl J Med
, vol.361
, pp. 123-134
-
-
Fong, P.C.1
Boss, D.S.2
Yap, T.A.3
-
52
-
-
77955019276
-
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
-
Tutt A, Robson M, Garber JE. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376: 235-244.
-
(2010)
Lancet
, vol.376
, pp. 235-244
-
-
Tutt, A.1
Robson, M.2
Garber, J.E.3
-
53
-
-
77955039099
-
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
-
Audeh MW, Carmichael J, Penson RT et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376: 245-251.
-
(2010)
Lancet
, vol.376
, pp. 245-251
-
-
Audeh, M.W.1
Carmichael, J.2
Penson, R.T.3
-
54
-
-
77951445939
-
Poly(ADP-ribose) polymerase inhibitors: a novel drug class with a promising future
-
Gartner EM, Burger AM, LoRusso PM. Poly(ADP-ribose) polymerase inhibitors: a novel drug class with a promising future. Cancer J 2010; 16: 83-90.
-
(2010)
Cancer J
, vol.16
, pp. 83-90
-
-
Gartner, E.M.1
Burger, A.M.2
LoRusso, P.M.3
-
55
-
-
39849097680
-
Resistance to therapy caused by intragenic deletion in BRCA2
-
doi: 10.1038/nature06548
-
Edwards SL, Brough R, Lord CJ et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008; 451: doi: 10.1038/nature06548.
-
(2008)
Nature
, pp. 451
-
-
Edwards, S.L.1
Brough, R.2
Lord, C.J.3
-
56
-
-
0029782022
-
Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy. University of Texas M. D. Anderson Cancer Center Experience
-
Diamandidou E, Au Buzdar, Smith TL et al. Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy. University of Texas M.D. Anderson Cancer Center Experience. J Clin Oncol. 1996; 14: 2722-2730.
-
(1996)
J Clin Oncol
, vol.14
, pp. 2722-2730
-
-
Diamandidou, E.1
Buzdar, Au.2
Smith, T.L.3
|